ADIL
AdialFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The post-earnings company update modestly improved the operating narrative by linking AD04 to a potentially more flexible FDA evidentiary framework, lower possible Phase 3 burden, European partnership discussions, and longer-dated IP protection if granted [#8-K-2026-05-11].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
AD04's Phase 3 path is still dependent on ongoing regulatory discussions and final trial design, so the hoped-for reduction in trial burden is not yet secured [#8-K-2026-05-11] [#10-Q-2026-05-08].
Momentum
71
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.60 · Bear $0.35
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $18.67
Why
Momentum71 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
71
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
0
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 71.2 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$6M
Beta
1.26
Shares Out
2.19M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.32
Rev YoY
-
EPS YoY
-82.7%
Gross Margin
-
Op Margin
-
Net Debt
-$5.88M
Current Ratio
3.18
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology